A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent

Trial Profile

A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2018

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Registrational; Therapeutic Use
  • Acronyms INSPIRE
  • Sponsors Onconova Therapeutics
  • Most Recent Events

    • 08 Mar 2018 According to an Onconova Therapeutics media release, more than half of the expanded study is now enrolled. The Company is planning to add sites in Europe and new territories, including in Latin America, in concert with Pint Pharma.
    • 05 Mar 2018 According to an Onconova Therapeutics media release, top-line data expected in 2019.
    • 12 Feb 2018 According to an Onconova Therapeutics media release, certain topline results anticipated on the one-month anniversary of the date.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top